Hyglos has a Solution Against Resistant Hospital Germs

29/05/2015 - 2 minutes

Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus. 

Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this protein, the natural microflora is maintained. This prophylactic treatment could counteract the spread of methicillin-resistant staphylococcus aureus (MRSA) in hospitals and, thereby, prevent patients from infections.

“We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational” explains Dr. Wolfgang Mutter from Hyglos GmbH.

According to experts, one person in three carries the bacterium Staphylococcus aureus in their nose. It is not dangerous in the case of healthy individuals, but can quickly become a problem if the carrier is admitted to a hospital. The pathogen can then insert inself into wounds and potentially cause dangerous infections,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member